LifeStance Health Group (NASDAQ:LFST – Get Free Report) announced its earnings results on Thursday. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02, Zacks reports. The business had revenue of $455.86 million for the quarter, compared to the consensus estimate of $431.59 million. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The firm’s revenue was up 25.3% on a year-over-year basis.
Here are the key takeaways from LifeStance Health Group’s conference call:
- Third-quarter revenue rose 25% to $456 million, driven by 17% growth in visit volume and a 7% increase in revenue per visit. Adjusted EBITDA increased 70% to $68 million, a 15% margin for the second consecutive quarter.
- LifeStance raised its full-year 2026 guidance: revenue to $1.741 billion–$1.761 billion and Adjusted EBITDA to $242 million–$250 million. The midpoint implies 23% revenue growth and roughly 300 basis points of year-over-year margin expansion.
- The clinician base grew 11% to 8,863, with 321 net additions in the quarter; management cited strong recruiting and stable retention. Visits per average clinician rose 5% year over year, which executives attributed partly to improved patient engagement.
- Specialty services revenue is expected to grow about 40% in 2026 to roughly $70 million, with management expecting a similar growth rate next year. The company is gradually expanding TMS and SPRAVATO, while citing positive outcomes data and opportunities to discuss coverage and reimbursement with payers.
- The new EHR rollout is expected to reduce 2027 revenue growth by approximately 1–2 percentage points, putting growth toward the lower end of LifeStance’s long-term mid-teens range. Management also previously estimated implementation costs of $20 million–$30 million; the phased rollout is expected to be completed by year-end 2027.
LifeStance Health Group Stock Up 2.5%
Shares of LifeStance Health Group stock traded up $0.34 during trading on Friday, reaching $13.77. The company had a trading volume of 4,924,487 shares, compared to its average volume of 3,459,394. The company has a market cap of $5.26 billion, a price-to-earnings ratio of 72.48 and a beta of 1.35. The firm’s fifty day moving average is $12.62 and its 200-day moving average is $9.49. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.38 and a current ratio of 1.44. LifeStance Health Group has a fifty-two week low of $5.87 and a fifty-two week high of $15.66.
Key LifeStance Health Group News
Here are the key news stories impacting LifeStance Health Group this week:
- Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
- Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
- Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high
Wall Street Analyst Weigh In
LFST has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. BTIG Research increased their price target on LifeStance Health Group from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday. Barclays lifted their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Thursday, September 10th. Finally, KeyCorp upped their target price on LifeStance Health Group from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.75.
View Our Latest Research Report on LFST
Insider Buying and Selling
In related news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the sale, the insider directly owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. The trade was a 12.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CTO Vukasin Paunovich sold 44,394 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $481,674.90. Following the completion of the sale, the chief technology officer directly owned 247,446 shares of the company’s stock, valued at approximately $2,684,789.10. This represents a 15.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 13,777,580 shares of company stock worth $146,433,781. Corporate insiders own 3.50% of the company’s stock.
LifeStance Health Group Company Profile
LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.
LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.
Read More
- Five stocks we like better than LifeStance Health Group
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
